JEFFS ROGER 4
4 · Axsome Therapeutics, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Axsome (AXSM) Director Roger Jeffs Sells Shares
What Happened Roger Jeffs, a director of Axsome Therapeutics (NASDAQ: AXSM), sold a total of 572 shares in two open‑market transactions. On 2026-06-10 he sold 286 shares at $246.18 for $70,407, and on 2026-06-11 he sold 286 shares at $249.12 for $71,248, for combined proceeds of approximately $141,655. These were sales (dispositions), not purchases.
Key Details
- Transactions: Open‑market sales (S) of 286 shares on 2026-06-10 at $246.18 ($70,407) and 286 shares on 2026-06-11 at $249.12 ($71,248).
- Total: 572 shares sold for ~ $141,655.
- Footnotes: (F1) Trades executed under a pre‑approved 10b5‑1 plan, which is now completed; (F2) shares sold to cover taxes from RSUs granted June 6, 2025.
- Shares owned after transaction: Not disclosed in the provided filing.
- Filing: Form 4 filed 2026-06-11 (covers transactions on 6/10 and 6/11); filing appears timely.
Context Sales executed under a pre‑existing 10b5‑1 plan and those to cover tax withholding on RSU settlements are common and often routine. Such transactions do not necessarily indicate a change in the insider’s view of the company. For investors, purchases by insiders tend to be more informative about confidence than routine sales.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-10$246.18/sh−286$70,407→ 58,653 total - Sale
Common Stock
[F1][F2]2026-06-11$249.12/sh−286$71,248→ 58,367 total
Footnotes (2)
- [F1]Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
- [F2]These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.